Abstract
The data show that with careful surgical technique, modern immunosuppression with MMF and FK506, and pancreatic allograft biopsy, it should be possible to achieve: 1) a low rate of technical complications, 2) improved long-term graft survival, particularly in solitary pancreas recipients improving the risk/benefit ratio of this option for nonuremic diabetics, 3) a high safety profile with combined MMF and FK506 immunosuppression, 4) safe transplantation using enteric drainage without increased risk of rejection, infection or graft loss, and 5) successful pancreas transplantation without induction therapy.
MeSH terms
-
Adolescent
-
Adult
-
Child
-
Child, Preschool
-
Diabetes Mellitus, Type 1 / surgery
-
Graft Rejection / epidemiology
-
Graft Survival
-
Hospitals, University
-
Humans
-
Immunosuppression Therapy / methods
-
Immunosuppressive Agents / therapeutic use
-
Middle Aged
-
Mycophenolic Acid / analogs & derivatives
-
Mycophenolic Acid / therapeutic use
-
Pancreas Transplantation / mortality
-
Pancreas Transplantation / physiology
-
Pancreas Transplantation / statistics & numerical data*
-
Patient Selection
-
Retrospective Studies
-
Survival Rate
-
Tacrolimus / therapeutic use
-
Time Factors
-
Tissue Donors / statistics & numerical data
-
Wisconsin
Substances
-
Immunosuppressive Agents
-
Mycophenolic Acid
-
Tacrolimus